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Abstract
Background/objectives: Vascular damage contributes to the high cardiovascular morbidity and mortality in end-
stage renal disease (ESRD). Increased aortic stiffness measured by carotid-femoral pulse wave velocity (cf-PWV) is a
strong and independent predictor of the cardiovascular risk in ESRD patients. Recently, there has been considerable
interest in developing strategies to lessen the progression of arterial stiffness in ESRD patients using cf-PWV as a
tool to monitor therapeutic responses, but their benefit on the long-term cardiovascular risk is not known. Appraisal
of the effects of existing stiffness-based interventions on the cf-PWV would facilitate selecting optimal therapies to
be tested in randomized clinical trials. The aim of this systematic review will be to evaluate the impact of arterial
stiffness-based interventions on the cf-PWV in ESRD patients. Secondarily, for each intervention, we will determine
the minimal duration needed to achieve a significant reduction of cf-PWV, the minimal cf-PWV reduction threshold
or effect size, and adverse events.
Methods/design: This review will be conducted using MEDLINE, EMBASE, and EBM Reviews. We will select clinical
trials and observational studies (cohort, case-control, and before/after studies and case series) that evaluated
pharmacologic or non-pharmacologic interventions in which the primary effect is to improve structural and/or
dynamic components of arterial stiffness in adults with stage 5 chronic kidney disease. The primary outcome of
interest will be cf-PWV. Study selection and data collection will be performed by two reviewers. Validated tools
will be used to assess the methodological quality and risk of bias among different study designs. We will describe
all included citations according to study characteristics, methodological quality, and outcomes. Suitability for meta-
analysis will be determined by the degree of clinical and statistical heterogeneity between studies. If appropriate,
we will calculate effect estimates by obtaining the relative risks with 95 % confidence intervals pooled according to
study design using a random effects model.
Discussion: This review will summarize evidence regarding effects of interventions targeting arterial stiffness in
ESRD patients. Our results will inform clinicians and researchers on the type of existing arterial stiffness-based
interventions for ESRD patients and their potential efficacy and safety, with a goal to guide future clinical trials
aimed at reducing adverse cardiovascular events.
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Background
Chronic kidney disease (CKD) is a major health burden
worldwide because of its high prevalence and associated
risk of end-stage renal disease (ESRD), cardiovascular
disease, and premature death. The age-standardized glo-
bal prevalence of CKD (stages 1–5) among adults
(≥20 years old) has been reported to be approximately
10.4 % for men (95 % CI, 9.3–11.9 %) and 11.8 % for
women (95 % CI, 11.2–12.6 %) [1]. In 2013, 956,200
deaths worldwide were reported to be directly attributed
to CKD, representing a 134.6 % increase from those re-
ported in 1990 [2]. Additionally, the high prevalence of
CKD has led to an increased prevalence of ESRD world-
wide and elevated health care costs. It is estimated that
in the period from 2000 to 2007, the total direct Medi-
care costs for ESRD in the USA alone increased from $
12.2 billion to $ 20.8 billion [3]. In Canada, the number
of people with ESRD in the last decade rose from 29,540
to 41,252, representing an increase of 40 % [4]. By the
end of 2013, 23,926 Canadians with ESRD were receiv-
ing some form of dialysis, but only 15 % of those were
on the waiting list for a renal transplant [4].
ESRD increases the risk of death by approximately 10
to 20 times compared to the general population [5]. Car-
diovascular disease accounts for almost 50 % of all
deaths in ESRD [5, 6]. Although occlusive thrombotic
coronary artery disease is common during the early
stages of CKD, in those who survive to reach ESRD re-
quiring dialysis, sudden death due to the presence of
arrhythmias, myocardial ischemia, and heart failure is
not uncommon [7, 8]. This phenomenon is associated
with accelerated atherosclerosis and vascular calcifica-
tion that leads to a loss of arterial compliance and in-
creased arterial stiffness, which in turn increases left
ventricle overload and decreases sub-endocardial per-
fusion [9, 10].
Arterial stiffness, defined as a decreased ability of the
conductive arteries to absorb the pulse pressure has
been reported to be a strong independent predictor of
overall cardiovascular mortality in the general popula-
tion [11, 12]. Since the aorta is the principal capacitive
element of the arterial tree, non-invasive measurements
of stiffness in the aorta obtained by applanation tonome-
try using the carotid-femoral pulse wave velocity (cf-
PWV) can more accurately reflect the physiologic effects
of increased arterial stiffness on the heart [13, 14]. In-
deed, elevated cf-PWV in ESRD patients who are treated
with peritoneal dialysis, hemodialysis, or renal trans-
plantation is an excellent predictor of fatal cardiovascu-
lar events and all-cause mortality [15–19]. An increase
of 1 m/s in cf-PWV in ESRD patients increases both
cardiovascular and overall mortality by 34 % by crude
estimates and by 14 % after adjusted analyses [20]. After
adjustment for potential confounders, ESRD patients
who have cf-PWV greater than or equal to 12.0 m/s are
five to six times more likely to die compared to those
patients with values less than 9.4 m/s [21].
Because of the excessive burden of cardiovascular dis-
ease in ESRD patients, there has been considerable inter-
est in developing strategies to lessen or delay the
progression of arterial stiffness in this high-risk group
[9, 22], using cf-PWV as a tool to monitor therapeutic
responses [11, 12]. The benefit of these interventions,
however, on the long-term cardiovascular risk of ESRD
patients is not known. A systematic appraisal of the effects
of existing stiffness-based interventions on the cf-PWV
would facilitate the selection of optimal therapies to be
tested in large randomized clinical trials. Accordingly, we
will conduct a systematic review of studies that have
explored the potential benefit of interventions on arterial
stiffness in humans with ESRD. Our knowledge synthesis
will examine the current clinical evidence on the impact
of interventions in ESRD patients directed at reducing ar-
terial stiffness, based on measures of cf-PWV.
Objectives
The primary objective of this review is to evaluate the
impact of stiffness-based therapeutic interventions on
the reduction of cf-PWV in ESRD patients. Secondary
objectives of our review will include the following: (1) to
determine the minimal duration of each intervention
needed to achieve a reduction of cf-PWV; (2) to define a
minimal cf-PWV reduction threshold or effect size for
each therapeutic option; and (3) to describe any reported
serious or non-serious adverse events associated with
the use of each intervention.
Methods and design
This review will be conducted in accordance with The
Cochrane Collaboration principles for Systematic Re-
views [23] and reported following the Preferred Report-
ing Items for Systematic Review and Meta-Analysis
(PRISMA) guidelines [24] and the PRISMA for abstracts
checklist [25]. The content of this protocol follows the
PRISMA Protocols (PRISMA-P) recommendations [26].
The checklist of the PRISMA-P recommendations is
included as an additional file (see Additional file 1). The
review protocol has been registered in PROSPERO




We will include adults (older than 18 years old) with se-
verely reduced kidney function (ESRD/CKD stage 5;
with an estimated glomerular filtration rate of less than
15 ml/min/1.73 m2) of any duration receiving or not
receiving renal replacement therapy. Kidney transplant
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recipients who are not on dialysis therapy will be in-
cluded if they had pre- and post-transplant assessments
of their cf-PWV.
Types of intervention
In ESRD patients, arterial stiffening develops from a com-
plex interaction between stable and dynamic changes in-
volving structural elements of the vessel wall as a result of
different factors such as increased wall stress from hyper-
tension, augmented extra-cellular matrix collagen content,
diffuse calcification, and vascular smooth-muscle cell pro-
liferation [28]. In this systematic review, we will incorpor-
ate any intervention in which the primary effect is to
improve the structural (qualitative and/or quantitative)
and/or dynamic components of arterial stiffness [22, 28].
This will include pharmacologic interventions aimed at
controlling blood pressure, vascular inflammation, and ar-
terial resistance (i.e., endothelin-A receptor antagonists)
or the plasma antioxidant status (i.e., vitamin E ana-
logues), to limit the progression of vascular calcification
(i.e., calcium-sensing receptor-inhibitors, agents that re-
store calcium/phosphorous imbalance) or atherosclerosis
(i.e., 3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitors) or to improve extra-cellular fluid volume fluctu-
ations (i.e., frequency/duration of dialysis, changes in
dialysate components, bio-impedance-guided fluid volume
control), renal replacement therapy (i.e., peritoneal dialysis,
hemodialysis, kidney transplantation), advanced glycation
end product inhibitors (i.e., aminoguanidine, alagebrium
chloride), and other non-pharmacologic therapies with po-
tential protective cardiovascular effects (i.e., physical fitness,
nutrition, exercise) [22, 28].
Comparators
There will be no restrictions on the type of comparator.
Placebo, supportive, or standard care and other thera-
peutic interventions will be accepted.
Outcomes
The primary outcome of interest will be cf-PWV defined
by arterial pulse wave measurements on the carotid and
femoral arteries in studies that have used previously
validated instrumentation. Secondary outcomes will in-
clude the following estimates associated with each inter-
vention: (a) minimal duration needed to achieve a
significant reduction of cf-PWV; (b) minimal cf-PWV
reduction threshold or effect size; and (c) any reported
serious or non-serious adverse events. We will consider
a serious adverse event as any untoward medical occur-
rence associated with the intervention that at any dose
may result in (a) death; (b) a life-threatening condition;
(c) in-patient hospitalization or prolongation of existing
hospitalization; (d) persistent or significant disability/
incapacity; or (e) a subsequent intervention to prevent
permanent functional impairment or damage [29].
Study design
Prospective clinical trials and observational studies (co-
hort, case-control, and before and after studies and case
series) will be included provided that 10 or more ESRD
participants have received the intervention and its effects
were assessed by cf-PWV.
Languages
We will include articles reported in the English,
French, Italian, and Spanish languages. A list of pos-
sibly relevant titles in any other language will be pro-
vided as an appendix.
Search strategy
Our search strategy will be conducted using MEDLINE,
EMBASE, Cochrane Central Databases, CADTH’s “Grey
Matters Light”, OVID, EBM Reviews, Health Technology
Assessment (HTA) database, and the gray literature of
studies published between January 1965 and March 2016
(see Additional file 2). EMBASE also includes the ab-
stract publications from major international conferences
including International, American, Canadian, Australian,
and New Zealand Societies of Nephrology as well as the
International, European, and Canadian Societies of
Hypertension. A comprehensive search strategy will be
constructed and implemented by a health information
specialist with systematic review experience, in collabor-
ation with the research team. MeSH terms will be used
to capture each of the principal elements of the research
question. Identified citations will be exported to a
citation manager for study selection. Manual review of
the reference lists of all included studies and previous
systematic reviews according to our pre-defined screen-
ing criteria will be conducted. The latter will be used as
an additional source of primary studies. A final gray lit-
erature search will be conducted using “Google Scholar”
as well as reviews of clinicaltrials.gov for any current
study. No language restriction will be utilized in any of
the initial searches, but our final analysis will be re-
stricted to citations published in English, French,
Spanish, or Italian. Duplicate citations will be removed,
and search strategies will be kept up to the time of the
end of the review.
Study screening and exclusions
Clinical trials and observational studies (cohort, case-
control, and before and after studies and case series) that
include stiffness-based interventions in ESRD patients will
be considered. Studies will also be considered if there has
been previous exposure of ESRD patients to an interven-
tion and if cf-PWV is one of the study outcomes. An
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iterative process for study selection will be followed using
the inclusion and exclusion criteria set out in Table 1. Spe-
cifically, the screening phase will include all prospective
and retrospective studies that report the effects of an
intervention on arterial stiffness (measured by cf-PWV) in
adult ESRD patients (age ≥18 years). We will exclude
studies that exclusively report on adult CKD stages 1 to 4
or pediatric populations (age <18 years), those that only
include kidney transplant patients without any pre-
transplant assessment of the cf-PWV, non-human studies,
narrative reviews, in vitro or mathematical modeling
reports, and any duplicate or sub-study of previously pub-
lished trials. Studies that exclusively report on different
markers of arterial stiffness such as brachial-ankle PWV,
ankle-brachial index, augmentation index, carotid-brachial
PWV, and femoral-tibial PWV will not be included in this
review. All citations will first be screened by title and
abstract. This process will be performed in duplicate by
two reviewers, and a third one for consensus in cases of
discrepancies. To facilitate the review at a text level, an
intermediate screening phase will be performed and the
methods section of each paper retrieved from the “title and
abstract” screening phase will be reviewed to confirm that
cf-PWV was the technique used to measure aortic stiffness,
that an appropriate instrumentation was used, that ESRD
patients were included, and that the characteristics of an
intervention were well documented. The intermediate
screening will be performed by one of the authors (RAR)
with a second reviewer independently checking for discrep-
ancies in only 20 % of the files. All citations not excluded
by the initial and intermediate screens will have full articles
retrieved for a subsequent review, in duplicate by two inde-
pendent reviewers, and the final selection criteria of Table 1
applied. Any differences in classification between the two
independent reviewers will be reviewed and consensus de-
cision made. We will record the reasons for excluding trials.
A third independent author will be asked to provide an in-
dependent opinion in all instances in which consensus is
not reached. Then, a judicious decision will be made based
on the option proposed by the independent reviewer. In
case of uncertainties on missing information about treat-
ments, methodology, and/or outcomes of included studies,
we will consider contacting study authors. Neither of the
review authors will be blind to the journal titles or to the
study authors or institutions.
Data extraction
A data extraction form will be prepared a priori through
consensus from all investigators and piloted prior to du-
plicate extraction by two independent reviewers. Data
extraction will include (a) study characteristics, design,
and methods: title, authors, journal/source/year and
Table 1 Study selection criteria
Descriptor Inclusion criteria Exclusion criteria
Patient
population
Adults (≥18 years old) with end-stage renal disease (ESRD) defined
as stage 5 chronic kidney disease (e-GFR <15 ml/min/1.73 m2) of
any duration and receiving or not any renal replacement therapy.
Kidney transplant recipients who are not on dialysis therapy will
be included if they had pre- and post-transplant assessments of
their cf-PWV.
Chronic kidney disease stages 1 to 4
Population-based studies that do not include ESRD patients
Non-human studies
Pediatric populations (<18 years of age)
Kidney transplant patients without any assessment of carotid-
femoral pulse wave velocity before transplantation
Intervention Any pharmacologic or non-pharmacologic intervention whose
primary effect is to improve the structural (qualitative and quantita-
tive) and/or dynamic components of arterial stiffness. This will in-
clude interventions aimed to control blood pressure or vascular
inflammation, to limit the progression of vascular calcification or
atherosclerosis, and to improve extra-cellular volume fluctuations,
renal replacement therapy, and advanced glycation end products.
Comparator A different intervention, placebo, control group, or patients
exposed to standard care ESRD management
Outcome Primary outcome: reduction on the carotid-femoral pulse wave
velocity defined by pulse wave measurements on the carotid and
femoral arteries using previously validated instrumentation and
proper methodological technique. Secondary outcomes will in-
clude the following estimates associated with each intervention:
(a) minimal duration needed to achieve a significant reduction of
cf-PWV; (b) minimal cf-PWV reduction threshold or effect size; and
(c) any reported serious or non-serious adverse events.
Studies that exclusively report on different markers of arterial
stiffness such as brachial-ankle PWV, ankle-brachial index, augmen-
tation index, carotid-brachial PWV and femoral-tibial PWV
Study
design
Clinical trials and observational studies (cohort, case-control, and
before and after studies and case series) (both prospective and
retrospective) provided that 10 or more ESRD participants have
received the intervention and its effects were assessed by cf-PWV)
Reviews, in vitro studies, mathematical models, duplicates or “sub-
cohorts” of previously published cohorts
Language English, French, Spanish, Italian
ESRD end-stage renal disease, cf-PWV carotid-femoral pulse wave velocity, e-GFR estimated glomerular filtration rate, PWV pulse wave velocity
Rodriguez et al. Systematic Reviews  (2016) 5:118 Page 4 of 7
language of publication, country, type of study design,
study period, publication status, total number of patients,
case ascertainment and/or inclusion/exclusion criteria, sin-
gle or multicenter study, randomization, allocation conceal-
ment, and blinding methods (where applicable); (b) sample
characteristics: age, sex, type of renal replacement therapy,
dialysis vintage and co-morbidities, duration of follow-up,
and type of arterial stiffness instrumentation used; (c) inter-
ventions and co-interventions: type of pharmacologic or
non-pharmacologic therapy utilized to limit the pro-
gression of arterial stiffness, its mechanism of action on
the components (structural and/or dynamic) of arterial
stiffness [22, 28], generic and trade names of the ex-
perimental intervention, dose, frequency and duration
of treatment, type of comparator and its dose, and
duration of follow-up; and (d) outcomes: reduction on
cf-PWV as primary outcome and the criteria used in
the definition of the effect size and its units of meas-
urement. We will also record the duration for each
stiffness-based therapy (when available), any reported
threshold of cf-PWV to differentiate between high and
low PWV, and clinical complications including mortal-
ity and other adverse events.
Analysis plan
A description of all included studies, including demo-
graphic, clinical, and methodological quality will be first
reported with the aid of tables and text. This narrative
synthesis will explain the relationships and findings
within and between the included studies in line with the
guidance from the Centre for Reviews and Dissemin-
ation [24]. Suitability for meta-analysis will be deter-
mined by the degree of heterogeneity (clinical and
statistical) observed between the studies. Statistical het-
erogeneity will be described using the I2 statistic. If
meta-analysis is feasible, we will calculate the effect mea-
sures by obtaining the relative risks with their 95 %
confidence intervals and pooled according to study de-
sign (randomized trials and observational studies, re-
spectively) using a random effects model.
Primary outcome
We anticipate that the primary outcome (reduction in
cf-PWV) may be reported differently according to the
study design. Some studies may report absolute or rela-
tive values that express the magnitude of reduction in
cf-PWV by the intervention while others may express
the results based on the proportion of patients above or
below a certain critical cf-PWV threshold. Results will
be expressed as continuous or dichotomous measures
depending on the reported outcome measure. Summar-
ies of continuous data will be presented as means and
mean differences with 95 % confidence intervals. Given that
a certain degree of heterogeneity is expected, a random
effects model will be used if we proceed to conduct a meta-
analysis. Statistical heterogeneity will be reported using the
I2 test with 95 % confidence interval.
Secondary outcomes
Secondary outcomes will be a combination of dichotom-
ous, ordinal, and continuous measures. All continuous
outcome variables will be described with means or me-
dians and associated standard deviations or interquartile
ranges as appropriate. Summaries of continuous data
will be presented as means and mean differences with
95 % confidence intervals.
Risk of bias
Risk of bias will be assessed using the “SIGN50” tool
[30] for observational studies (cohort and case-control
studies) and the Cochrane Collaboration tool for asses-
sing the risk of bias in randomized clinical trials [31].
The assessment of the risk of bias will be performed in
duplicate by two independent evaluators. Any discrep-
ancy not resolved by consensus will be reviewed by a
third senior author. Risk of bias assessment of all in-
cluded studies will be summarized and presented in
table format. If possible, we will perform meta-analysis
with a planned sensitivity analysis using only those stud-
ies with low risk of bias and high methodological quality.
Low risk of bias will be defined as those studies where
the majority of criteria for methodological quality are
met with little or no risk of bias (“++”) using the
SIGN50 tool or those deemed low risk across all do-
mains of the Cochrane’s collaboration tool for assessing
risk of bias. For observational studies, criteria will in-
clude quality of data reporting, high internal and exter-
nal validity, low risk of confounding, and sufficient study
power. If there are sufficient number of trials (i.e., ≥10
studies), we will construct a funnel plot to assess for
possible publication bias.
Sub-group analyses
Pre-planned sub-group analysis to examine clinical
heterogeneity will include, if possible, dialysis vintage
(≥2 vs <2 years), diabetes mellitus (diabetic vs non-
diabetics), age subgroups (≥50 vs <50 years), and type of
renal replacement therapy (pre-dialysis, peritoneal dialysis,
conventional hemodialysis, frequent hemodialysis, and
renal transplantation).
Sensitivity analyses
To improve the robustness of our findings, our pre-
planned sensitivity analyses will include the following:
(a) studies with low versus high/unclear risk of bias;
(b) studies conducted after 2005 (when arterial stiff-
ness was recognized by a consensus of international
experts as a target for therapeutic options aimed to
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improve cardiovascular outcomes) [32, 33]; and (c)
studies with follow-up ≥12 months (as a sustained ef-
fect of the intervention is expected).
Confidence in cumulative estimate
If we find sufficient information in the literature for the
different types of stiffness-based interventions, we will
attempt to apply the GRADE methodology to rate the
quality of the body of evidence and recommendations as
high, moderate, low, or very low quality [34].
Amendments
In the event of protocol amendments, we will provide
the date of each amendment in a tabular form with the
description of the changes and rationale.
Discussion
Increased arterial stiffness exerts a number of adverse ef-
fects on cardiovascular function and is associated with
heightened mortality in patients with ESRD [10, 14, 16,
18, 20, 21, 35]. Thus, the prevention and treatment of
elevated arterial stiffness is important in this high-risk
population. Evidence indicates that certain strategies
whose mechanism targets the dynamic and/or structural
components of vascular stiffness appear to be clinically
efficacious interventions for preventing the progression
of arterial stiffness [9, 10, 22, 28, 33, 35]. These interven-
tions seem to have variable effectiveness in ESRD patients
and are often not clearly defined [22, 28]. Whether com-
bined stiffness-based therapies would provide better
survival benefit compared with single interventions in
ESRD patients, it will require testing in large randomized
controlled trials. Thus, a systematic appraisal of existing
stiffness-based interventions would facilitate selection of
optimal therapies to be evaluated in those clinical trials.
This review proposes to systematically identify, assem-
ble, and summarize the existing evidence regarding the
effects of pharmacologic and non-pharmacological inter-
ventions targeting aortic stiffness in ESRD patients. We
will also summarize evidence on the duration of inter-
ventions and the minimal cf-PWV reduction threshold,
effect size, and adverse events associated with each inter-
vention. These results will inform decisions affecting the
design of clinical trials and will serve as a summation of
the evidence to guide clinical decisions at the bedside.
Since we expect that the majority of available evidence
will have been generated by observational and cohort
studies rather than randomized controlled trials, we have
planned for a large descriptive component of this review.
To minimize the impact of potential risk of bias in these
studies, we have incorporated validated tools that will
assess the methodological quality and risk of bias among
cohort and case-control studies, in addition to measures
of clinical and statistical heterogeneity. Two recent meta-
analyses have provided strong evidence that aortic PWV
improves risk prediction for cardiovascular disease and
mortality in the general population, beyond conventional
risk factors [11, 12]. Most studies included in the analysis
were observational and performed in hypertensive patients
or the general population, except for three studies in
ESRD patients. These analyses indicated that the pooled
age and sex adjusted hazard ratio (HR) for cardiovascular
events per 1-SD change in the cf-PWV was 1.35 (95 % CI,
1.22 to 1.50) for coronary artery disease, 1.54 (95 % CI,
1.34–1.78) for stroke, and 1.45 (95 % CI, 1.30–1.61) for
cardiovascular disease. A sub-group analysis confirmed
that an elevated cf-PWV in the presence of chronic
kidney disease (stages 3 to 5) increased the risk for
cardiovascular events by 48 % (HR, 1.48; 95 % CI,
1.24–1.76). Thus, these results support the notion that
cf-PWV may be a suitable target for novel risk reduc-
tion strategies and that attenuation on the cf-PWV
could be associated with improved survival.
Acceptance of cf-PWV as a useful biomarker for guid-
ing risk stratification and/or treatment in ESRD depends
on providing convincing evidence through randomized
controlled trials. Our proposed knowledge synthesis will
not only inform clinicians and researchers as end-users
on the types and effects of existing interventions that
target regression of arterial stiffness in ESRD but will
also provide information on the efficacy and safety of
these interventions to guideline producers and health
policy makers. This review will also highlight weaknesses
in study design and thereby inform future studies to re-
duce arterial stiffness with a goal to prevent adverse car-
diovascular events in ESRD patients.
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